Back to results
US 5,705,510 AGranted
Use of cabergoline and related ergoline derivatives for controlling intraocular pressure
AssigneeAlcon Laboratories, Inc.
InventorsLouis DeSantis, Jr., Verney L. Sallee, Marsha A. McLaughlin, Manoj L. Maniar
Life of this patent
Estimating the term…
Abstract
The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.
Claims9
A method of controlling elevations of intraocular pressure which comprises applying to the eye a therapeutically effective amount of a topical ophthalmic composition comprising an amount of a compound of the following formula effective to control intraocular pressure:
- ##STR3## wherein:
- R.sub.1 represents a hydrogen atom or a methyl group;
- R.sub.2 represents a hydrogen or halogen atom, a methyl or formyl group or a group of the formula S--R.sub.7 or SO--R.sub.7, wherein R.sub.7 represents an alkyl group having from 1 to 4 carbon atoms or a phenyl group;
- R.sub.3 represents a hydrogen atom or a methoxy group;
- R.sub.4 represents a hydrocarbon group having from 1 to 4 carbon atoms, benzyl or phenethyl;
- and
- X is OH or NR.sub.5 CONHR.sub.6, wherein each of R.sub..sub.5 and R.sub.6 independently represents an alkyl group having from 1 to 4 carbon atoms, a cyclohexyl group or a substituted or unsubstituted phenyl group or an acid and water-soluble group such as (CH2).sub.n N(CH3).sub.2 in which n is an integer, with the proviso that R.sub.5 and R6 cannot both be a said acid and water soluble group;
- and a pharmaceutically acceptable vehicle therefor.
5 more elements
Dependencies are inferred from the claim text.